Fasting Versus Nonfasting Triglycerides and the Risk of Cardiovascular Events by Nosovitsky, Gennady
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Summer 8-10-2013
Fasting Versus Nonfasting Triglycerides and the
Risk of Cardiovascular Events
Gennady Nosovitsky
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Nosovitsky, Gennady, "Fasting Versus Nonfasting Triglycerides and the Risk of Cardiovascular Events" (2013). School of Physician
Assistant Studies. Paper 431.
Fasting Versus Nonfasting Triglycerides and the Risk of Cardiovascular
Events
Abstract
Background: ATP III guidelines suggest a 9- to 12-hour fast before obtaining lipid levels. Various
publications have challenged this practice citing postprandial hypertriglyceridemia as a risk for cardiovascular
events. Although this association is not entirely certain, it does raise into question the requirement for
obtaining fasting lipoprotein measurements.
Method: Exhaustive literature search was conducted using multiple search engines, with keywords related to
lipids, postprandial time and cardiovascular events. Relevant studies were assessed for quality of evidence
using GRADE.
Results: Three prospective cohort studies met inclusion criteria. All studies included fasting and nonfasting
plasma triglycerides, which were about ~15% higher in the nonfasting group. First study had 19 983 fasting
and 6347 nonfasting female participants. Cardiovascular events HR for postprandial hypertriglyceridemia was
1.22 (95% CI 1.12-1.33) and 1.23 (95% CI 1.16-1.30) in the fasting. Further adjusting for total and HDL-
cholesterol, showed an HR 1.17 (95% CI 1.04-1.31) and 1.07 (95% CI 1.00-1.15), respectively. Second study
included 20 118 fasting and 6391 nonfasting female participants. When adjusted for all possible variables, the
nonfasting group showed an HR of 1.98 (95% CI 1.21-3.25) and 1.09 (95% CI 0.85-1.41) for the fasting
group. Third study included 2809 men, who, at baseline, had both fasting and nonfasting triglycerides
measured. At an 8-year follow-up, cardiovascular event HR was 1.64 (95% CI 1.17-2.29) and 1.46 (95% CI
1.03-2.07) for fasting and nonfasting triglycerides ≥200 mg/dL, respectively. At 18-year follow-up, HR for
cardiovascular-associated death in the fasting cohort was 0.93 (95% CI 0.61-1.41) versus 1.60 (95% CI
1.05-2.45) for nonfasting.
Conclusion: All of the studies reviewed showed nonfasting triglycerides to be an independent risk factor for
cardiovascular events. However, risk with fasting levels was not as consistent. At this time, fasting is standard
practice, but in certain patients, checking nonfasting lipids may be appropriate.
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Abstract   
Background:  ATP III guidelines suggest a 9- to 12-hour fast before obtaining lipid 
levels.  Various publications have challenged this practice citing postprandial 
hypertriglyceridemia as a risk for cardiovascular events.  Although this association is not 
entirely certain, it does raise into question the requirement for obtaining fasting 
lipoprotein measurements.   
 
Method:  Exhaustive literature search was conducted using multiple search engines, with 
keywords related to lipids, postprandial time and cardiovascular events.  Relevant studies 
were assessed for quality of evidence using GRADE.   
 
Results:  Three prospective cohort studies met inclusion criteria.  All studies included 
fasting and nonfasting plasma triglycerides, which were about ~15% higher in the 
nonfasting group.  First study had 19 983 fasting and 6347 nonfasting female 
participants.  Cardiovascular events HR for postprandial hypertriglyceridemia was 1.22 
(95% CI 1.12-1.33) and 1.23 (95% CI 1.16-1.30) in the fasting.  Further adjusting for 
total and HDL-cholesterol, showed an HR 1.17 (95% CI 1.04-1.31) and 1.07 (95% CI 
1.00-1.15), respectively.  Second study included 20 118 fasting and 6391 nonfasting 
female participants.  When adjusted for all possible variables, the nonfasting group 
showed an HR of 1.98 (95% CI 1.21-3.25) and 1.09 (95% CI 0.85-1.41) for the fasting 
group.  Third study included 2809 men, who, at baseline, had both fasting and nonfasting 
triglycerides measured.  At an 8-year follow-up, cardiovascular event HR was 1.64 (95% 
CI 1.17-2.29) and 1.46 (95% CI 1.03-2.07) for fasting and nonfasting triglycerides ≥200 
mg/dL, respectively.  At 18-year follow-up, HR for cardiovascular-associated death in the 
fasting cohort was 0.93 (95% CI 0.61-1.41) versus 1.60 (95% CI 1.05-2.45) for 
nonfasting. 
 
Conclusion:  All of the studies reviewed showed nonfasting triglycerides to be an 
independent risk factor for cardiovascular events.  However, risk with fasting levels was 
not as consistent.  At this time, fasting is standard practice, but in certain patients, 
checking nonfasting lipids may be appropriate. 
 
Keywords:  Lipid, lipoprotein, triglyceride, fasting, nonfasting, cardiovascular events 
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  Fasting Versus Nonfasting Triglycerides and the Risk of Cardiovascular Events 
BACKGROUND 
Routine measurement of cholesterol has become a cornerstone of primary 
care, in both screening and monitoring of hyperlipidemia, given the well established link 
between cardiovascular disease and hyperlipidemia.14,15,16,17,18,24  Current 
recommendation guidelines on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults – Adult Panel III (ATP III) from the National Institute of Health 
(NIH) suggest a 9- to 12-hour fast before obtaining lipid or lipoprotein levels.  However, 
if nonfasting lipids are obtained, only Total Cholesterol and high-density lipoprotein 
(HDL) levels should be used for any clinical decision making, given the variability in 
triglycerides and thus low-density lipoproteins (LDL), since LDL levels are calculated 
based on measured triglycerides.7,25  Various publications however, challenge the current 
paradigm of measuring fasting lipoproteins, especially triglycerides, and argue for 
nonfasting measurements instead.3,16,17,18  Recent studies have shown postprandial 
hypertriglyceridemia as a risk factor for developing cardiovascular events and thus 
posing a question of whether it is really necessary to obtain fasting lipids.2,6,11,12,21,24  If 
the data demonstrates a push towards lifting the recommendation for fasting lipoprotein 
measurements, this may not only influence the practice of many primary care providers, 
but can also increase compliance with lipid testing, since it does not require patients to 
return for follow-up, without jeopardizing patient care.21 
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METHODS 
An exhaustive literature search was conducted using the following search 
engines: MEDLINE-Ovid, Web of Science, CINAHL and EBMR Multifile; using the 
following keywords: nonfasting, postprandial, lipids, triglycerides and cardiovascular 
event.  References of all eligible studies were also reviewed for relevant articles.  
Inclusion criteria used: adult population, studies having both fasting and a nonfasting 
group and the influence on cardiovascular events.  All studies investigating drug 
intervention on lipid profiles and outcomes were excluded.  All relevant studies were 
assessed for quality of evidence using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE). 
RESULTS 
 
Initial literature search resulted in 192 articles.  After reviewing the 
articles based on the eligibility criteria and removing duplicates, a total of three studies 
met the criteria.  All three studies were prospective cohort studies.2,6,12 
Mora et al 
This was a prospective cohort trial12 which evaluated plasma lipid 
concentration at various postprandial times and determined if fasting versus nonfasting 
status differs in predicting cardiovascular events.12 
Fasting status was defined as having last meal ≥8-hours prior to 
phlebotomy.  Two groups were compared, fasting versus nonfasting, and then further 
divided according to time since last meal.  The nonfasting female cohort comprised of 
6347 participants.  The fasting group included 19 983 female participants.  Each group 
was then subdivided based on time since last meal in 2-hour intervals.  The nonfasting 
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group was divided into the following groups:  <2-hours (n=991), 2 to <4 (n=2782), 4 to 
<6 (n=1702), and 6 to 8 (n=872); while the fasting group was divided into the following 
groups: 8 to <10 (n=1321), 10 to <12 (n=3490), 12 to <14 (n=8550), 14 to <16 (n=5196) 
and >16-hours (n=1426).  The primary end-point recorded was the incidence of a 
cardiovascular event, which the study defined as nonfatal myocardial infarction (MI), 
percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), 
nonfatal stroke or cardiovascular-related death.12 
During the 11.4-year follow up, there were a total of 961 cardiovascular 
events, 754 (3.8%) in the fasting group and 207 (3.3%) in the nonfasting group.  When 
compared with fasting lipids, nonfasting lipids showed about 1-5% lower concentration 
of total cholesterol (TC), low-density lipoprotein (LDL), apolipoprotein-B-100, non-
high-density lipoprotein (non-HDL), and apolipoprotein-B-100:A-1 ratio levels.  
Triglycerides, however, were about 15% higher in the nonfasting group.  The results 
(Table 2) further showed a significant risk of a cardiovascular event in the setting of 
elevated postprandial triglycerides when compared with fasting concentration, HR 1.22 
(95% CI 1.12-1.33) and 1.23 (95% CI 1.16-1.30), respectively.  However, when further 
adjusted for total and HDL-cholesterol, showed an HR 1.17 (95% CI 1.04-1.31) and 1.07 
(95% CI 1.00-1.15), for nonfasting and fasting, respectively.  However, the study did find 
that for TC, LDL, apolipoprotein-B-100, non-HDL, and apolipoprotein-B-100:A-1 ratio, 
fasting levels were better associated with a cardiovascular event.  HDL, apoliprotein-A-1, 
and TC:HDL ratio were comparable.  The study also assessed to see if time of day had 
any influence on lipid levels or risk and this was found to not be of any clinical 
significance.12 
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The study did have some limitations.  First, only women participated in 
the study.  Thus the results may not be able to be applied to male and non-white patients 
in a clinical setting.  However despite the limitations, the study does suggest fasting lipids 
may not be necessary when assessing levels of HDL or triglycerides.12 
Bansal et al 
This is a prospective cohort study2 which compared fasting and nonfasting 
triglycerides and the incidence of a cardiovascular event in a female population.  Of the 
26 509 women participants, there were 20 118 in the fasting group and 6391 in the 
nonfasting group.  The outcomes assessed were cardiovascular events, which included 
myocardial infarction, ischemic stroke, coronary revascularization, or cardiovascular 
related-death.  Data analyses was adjusted for aspirin, age, blood pressure, smoking status 
and hormone replacement therapy (HRT).2  Fasting was defined as nothing by mouth for 
at least 8-hours prior to phlebotomy.  Follow-up was 11-years. 
Each group was subdivided into three-tertiles, which were based on 
plasma triglyceride concentration.  Each tertile was then subanalysed using three 
adjustment-models, which controlled for different variables.  Model 1 adjusted for age, 
blood pressure, smoking, and the use of HRT; Model 2 adjusted for all variables in 
Model 1 plus additionally for total and high-density lipoprotein cholesterol (HDL-C); 
Model 3 included Model 2 plus diabetes mellitus, body mass index (BMI), and high C-
reactive protein (CRP) levels.2  Data was reported in terms of hazard ratios, as illustrated 
in Table 3. 
When controlling for all variables, nonfasting triglycerides showed higher 
HR for tertile-3, triglyceride concentration ≥171 mg/dL, compared to fasting levels.  
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Further data review, showed statistical significance for a link between postprandial 
triglycerides concentration and cardiovascular events when lipid levels were checked 2- 
to 4-hours after a meal, but not when measured within 2-hours.2 
In their comments, the authors describe that postprandial 
hypertriglyceridemia showed an independent risk for a CV event, compared with that of 
fasting concentration, and was most significant at 2- to 4-hours postprandially.2  
However, the study does have several limitations.  First, participants were not 
randomized to the assigned groups, though baseline characteristics were similar between 
the groups.  Second, only female participants were included in the study and thus 
extrapolating the data to male patients is probably not recommended.2  Third, no ethnicity 
of the study participants was provided, thus applying the data to other ethnic groups 
maybe somewhat problematic.  However, despite the limitations, the study does 
ultimately recommend moving towards measuring postprandial rather than fasting 
lipoprotein concentrations, citing study strengths of “large sample size, extended follow-
up time with validated outcomes and measurement of both fasting and nonfasting levels 
of triglycerides within the same cohort.”2  The authors also point out that “postprandial 
levels are a more robust indicator of cardiovascular risk, perhaps because the greater 
variability of postprandial levels captures important information about an individual’s 
metabolism.”2 
Eberly et al 
This was a prospective cohort trial comparing both fasting and nonfasting 
triglyceride measurements and to determine the implication for developing coronary heart 
disease (CHD) based on triglyceride concentration.  The study included 2809 men, who, 
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at baseline, had both fasting and nonfasting lipoprotein measurement, with particular 
emphasis on plasma triglyceride concentration.6 
The authors report baseline mean triglyceride concentration of 187 mg/dL 
(±135 mg/dL) and 284 mg/dL (±193 mg/dL) for the fasting and nonfasting groups, 
respectively.  Of the 2809 participants, 874 (31%) had fasting triglyceride levels ≥200 
mg/dL, compared to 1724 (61%) in the nonfasting group.6 
Follow-up was approximately 25.4 years.  During that time period, there 
were a total of 117 deaths (13.4%) in the fasting group (HR, 1.24, 95% CI 0.97-1.60) 
among those with triglyceride concentration of ≥200 mg/dL, compared to 226 deaths 
(13.1%) in the nonfasting group (HR, 1.26, 95% CI 0.98-1.62).  There were also reports 
of 211 deaths (10.9%) in participants with triglyceride concentration of <200 mg/dL in 
the fasting group, versus 102 deaths (9.4%) in the nonfasting group (Table 4).6  The 
authors reported a cardiovascular event HR of 1.64 (95% CI 1.17-2.29) and 1.46 (95% CI 
1.03-2.07) for fasting and nonfasting plasma triglycerides ≥200 mg/dL, respectively, at 8-
year follow-up.  However, at the 18-year follow-up, HR for cardiovascular-associated 
death in the nonfasting cohort was 1.60 (95% CI 1.05-2.45), compared to 0.93 (95% CI 
0.61-1.41) in the fasting.6 
The authors describe a limitation of not determining time since last meal.6 
However this may not indicate a limitation, but rather represent true everyday clinical 
practice.  Thus, in addition to the results, the authors make a case for the utilization of 
nonfasting lipid levels given the convenience of obtaining nonfasting measurement, 
higher prevalence for postprandial hypertriglyceridemia and similar risk compared to that 
of fasting.  
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DISCUSSION 
 
It is well documented that hyperlipidemia is a risk factor for 
cardiovascular disease and fasting lipoprotein measurements, according to ATP III 
recommendation guidelines, is currently considered the standard of care when assessing a 
patient’s lipid profile.25  In a clinical setting this creates an inconvenience for patients and 
providers alike.  However recent studies have raised doubt as to the need to measure 
fasting lipids and thus changing clinical practice.1,3,9,13,16,17,18,21,22,23,24 
The studies in this review directly compared fasting versus nonfasting 
lipid concentration as a risk factor for cardiovascular events.2,6,12  Two of the studies2,6 
focused specifically on triglyceride concentration, whereas Mora et al12 included all 
fractions of a clinically available lipid panel.12 
When examining the correlation between fasting versus nonfasting plasma 
triglyceride concentration and the risk for developing cardiovascular events, Mora et al12 
and Eberly et al6 both showed a statistically significant correlation for such events in the 
setting of hypertriglyceridemia, without regard to time since last food intake.  In the Mora 
et al12 study, each 1-SD increase in plasma triglyceride concentration demonstrated an 
HR of 1.23 (95% CI 1.16-1.30) and 1.22 (95% CI 1.12-1.33) for fasting and nonfasting 
levels, respectively.  Although, when further adjusted for total cholesterol and HDL, the 
HR for fasting was 1.07 (95% CI 1.00-1.15) and 1.17 (95% CI 1.04-1.31) for 
nonfasting.12  Eberly et al6 similarly reported a cardiovascular event HR of 1.64 (95% CI 
1.17-2.29) and 1.46 (95% CI 1.03-2.07) for fasting and nonfasting plasma triglycerides 
≥200 mg/dL, respectively, at 8-year follow-up.6  However, at the 18-year follow-up, HR 
for cardiovascular-associated death in the nonfasting cohort was 1.60 (95% CI 1.05-
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2.45), compared to 0.93 (95% CI 0.61-1.41) in the fasting (Table 4).  Furthermore, in the 
Bansal et al2 study, when adjusted for all possible variables such as age, blood pressure, 
smoking, HRT, HDL, diabetes, BMI, and high CRP levels (Model 3), the nonfasting 
tertile-3 group showed an HR of 1.98 (95% CI 1.21-3.25) compared to 1.09 (95% CI 
0.85-1.41) for the fasting group.2 
Despite the finding of postprandial hypertriglyceridemia as a risk for a 
cardiovascular event, Mora et al12 also found a statistically significant risk for each 1-SD 
increment increase in measured low-density lipoprotein (LDL) when obtained ≥9-hours 
after a meal (HR 1.21 [95% CI 1.13-1.29]) compared to a nonfasting measurement (HR 
1.00 [95% CI 0.87-1.15]).  This was despite statistically significant lower LDL 
concentration in the nonfasting group,12 which was consistent with other studies showing 
lower postprandial LDL concentrations.4,5,11,21,28  The authors in the Mora et al12 study, 
however, did not provide an explanation as to why fasting LDL showed to be a better 
predictor for cardiovascular disease, compared to nonfasting, despite lower 
concentrations postprandially.  The authors also did not comment as to whether any of 
the study participants were on statin (HMG-CoA inhibitor) lipid-lowering therapy.  
Although it is unlikely for the study participants to be on any lipid-lowering agents 
during the time of the trial, it is possible that those in the fasting group were counseled 
more aggressively given their higher fasting LDL levels.  
The data showing statistically significant risk with postprandial 
hypertriglyceridemia presents clinicians with flexibility when obtaining lipoprotein levels 
in a nonfasting individual.  In a clinical setting, providers frequently have to decide 
whether to have the afternoon patient come back in the morning after at least a 9-hour 
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fast or to allow for nonfasting measurements.  This may provide clinicians with some 
guidance on interpreting nonfasting lipoprotein measurements.  If a nonfasting lipid 
concentration is obtained, providers can base their clinical decision-making on 
triglycerides and total:HDL-cholesterol ratio, with an understanding that the LDL levels 
will be lower by approximately 1-5%.12  Consequently, this poses an important clinical 
question as to how providers proceed with regard to pharmacological interventions given 
that most lipid-lowering trials were done with participants being in the fasting state,16 
making nonfasting lipid measurements to some extent ambiguous.  Future large 
multicenter clinical trials will be very useful in clarifying how lipid-lowering agents may 
influence cardiovascular event outcomes in the setting of postprandial 
hypertriglyceridemia. 
Using the GRADE system, studies 2,6,12 were reviewed for quality of 
evidence (Table 1).  All three individual studies showed “low” level in the assessment of 
the quality of evidence.  In the Bansal et al2 and Mora et al12 studies, the authors reported 
several limitations.  First, time to last meal was patient-self-reported.  Second, the study 
only included female participants “who were mostly white,”12 although the exact 
ethnicity percentage was not reported.2,12  Although these limitations preclude clinicians 
from extrapolating the data to males and potentially other ethnic groups, it was felt that 
this did not warrant a downgrade.  All other categories (inconsistency, indirectness, 
imprecision and publication bias) were assessed and no discrepancies were noted.  Bansal 
et al2 and Mora et al12 both had a significantly large cohort of participants, with Mora et 
al12 also reporting comprehensive data for all clinically available lipoprotein 
measurements.  
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CONCLUSION 
Despite the recommendation for obtaining plasma lipoprotein 
measurements in the fasting state, several studies have questioned this practice, raising 
the argument that postprandial hypertriglyceridemia is a risk factor for cardiovascular 
events.  All of the studies reviewed herein did show nonfasting plasma triglycerides to be 
an independent risk factor for cardiovascular events.  However, when it came to fasting 
plasma triglycerides, the same consistency and correlation across the studies could not be 
found.  Although, at this time, using a fasting lipid profile is standard practice – given the 
results of the aforementioned studies – in certain patients obtaining nonfasting lipid 
profile may be more convenient as compliance may be an issue. However, there are 
currently no formal recommendations to suggest this practice and further studies are 
needed to corroborate the findings mentioned above. 
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TABLE 1  GRADE Quality Assessment 
Study Design Limitations Inconsistency Indirectness Imprecision Publication Bias Quality 
Mora et al Prospective Cohort None None None None Unlikely Low 
Bansal et al Prospective Cohort None None None None Unlikely Low 
Eberly et al Prospective Cohort None None None None Unlikely Low 
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TABLE 2  Mora et al study, cardiovascular events rate, adjusted hazard ratios 
 aP<0.05,  *P=NS 
 
 
 
TABLE 3  Bansal et al study, fasting and nonfasting Hazard Ratios for each tertile 
 Tertile 1 Tertile 2 Tertile 3 
Fasting triglycerides, mg/dL ≤90 91-147 ≥148 
Model 1a 1 [reference point] 1.63 (1.31-2.02) 2.23 (1.82-2.74) 
Model 2b 1 [reference point] 1.27 (1.02-1.59) 1.32 (1.03-1.68) 
Model 3c 1 [reference point] 1.21 (0.96-1.52) 1.09 (0.85-1.41) 
Nonfasting triglycerides, 
mg/dL ≤104 105-170 ≥171 
Model 1a 1 [reference point] 1.48 (0.95-2.29) 2.53 (1.69-3.79) 
Model 2b 1 [reference point] 1.31 (0.83-2.05) 1.94 (1.21-3.10) 
Model 3c 1 [reference point] 1.44 (0.90-2.29) 1.98 (1.21-3.25) 
aAdjusted Hazard Ratios (95% CI) for age, blood pressure, smoking, and use of hormone therapy 
bAdjusted HR (95% CI) model 1 plus total and high-density lipoprotein cholesterol (HDL-C) 
cAdjusted HR (95% CI) for model 2 plus diabetes mellitus, body mass index, and high C-
reactive protein levels. 
 
 
 
 
 Fasting (n = 19 983) Nonfasting (n = 6347)  
Cardiovascular Events, No (%) 754 (3.8%) 207 (3.3%) 
 
Adjusted Hazard Ratios (95% CI)  
per 1-SD increment increase 
Triglycerides 1.23 (1.16-1.30)a 1.22 (1.12-1.33)a 
Triglycerides, adjusted for total 
and HDL-cholesterol 1.07 (1.00-1.15)
* 1.17 (1.04-1.31)a 
Total:HDL-cholesterol ratio 1.36 (1.27-1.45)a 1.28 (1.15-1.44)a 
Total Cholesterol 1.22 (1.14-1.30)a 1.07 (0.93-1.21)* 
LDL 1.21 (1.13-1.29)a 1.00 (0.87-1.15)* 
HDL-cholesterol 0.79 (0.72-0.86)a 0.75 (0.64-0.89)a 
Non-HDL 1.29 (1.21-1.38)a 1.15 (1.01-1.31)a 
Apolipoprotein A-1 0.82 (0.75-0.89)a 0.86 (0.73-1.00)a 
Apolipoprotein B-100 1.36 (1.27-1.45)a 1.20 (1.05-1.36)a 
Apolipoprotein B-100:A-1 ratio 1.39 (1.30-1.48)a 1.18 (1.09-1.27)a 
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  TABLE 4  Eberly et al study, cardiovascular events hazard ratios 
 
Triglyceride concentration, mg/dL 
<200 ≥200 
FASTING n = 1935 n = 874 
Cardiovascular Events,  
8-year follow-up, No (%) 
[HR (95% CI)] 
102 (5.3%) 
 
73 (8.4%)  
[1.64 (1.17-2.29)] 
HR (95% CI) for death,  
18-year follow-up n/a 0.93 (0.61-1.41) 
Deaths, 25-year follow-up, No (%) 
[HR (95% CI)] 
211 (10.9%) 117 (13.4%)  
[1.24 (0.97-1.60)] 
 
Non-FASTING n = 1085 n = 1724 
Cardiovascular Events,  
8-year follow-up, No (%) 
[HR (95% CI)] 
50 (4.6%) 
 
125 (7.3%)   
[1.46 (1.03-2.07)] 
HR (95% CI) for death,  
18-year follow-up n/a 1.60 (1.05-2.45) 
Deaths, 25-year follow-up, No (%) 
[HR (95% CI)] 
102 (9.4%) 226 (13.1%)  
[1.26 (0.98-1.62)] 
 
 
 
